Why the study?
Literature describing the usage of ivabradine for supraventricular tachycardia in the pediatric age group is scarce.
Does ivabradine improve refractory focal atrial tachycardia in a neonate?
Case Report (n=1)
No
Does ivabradine improve refractory focal atrial tachycardia in a neonate?
Ivabradine may be an effective and safe treatment option for refractory focal atrial tachycardia in neonates, potentially avoiding the need for high-risk radiofrequency ablation.
Answers are grounded in this paper and cite their sources.
May support ivabradine in refractory neonatal atrial tachycardia; hypothesis-generating and requires prospective trials.
Supraventricular tachycardia (SVT) is a clinical condition caused by many arrhythmias and from different etiologies. Any arrhythmogenic focus above the ventricles due to reentrant or isolated ectopic focus can cause SVT. Neonates usually tolerate tachy- and bradyarrhythmias better than any other age groups. In SVT, the signs of cardiac failure appear after at least 36–48 hrs. We are here presenting a case report of SVT caused by unifocal atrial ectopic focus and treated by ivabradine as it was not responding to usual antiarrhythmic drugs. Literature showing the usage of ivabradine in SVT in pediatric age group is scarce; therefore, we are reporting this case.
No takes yet. Share an insight, caveat, or question.
Taduri et al. (2019) conducted a case report in Supraventricular tachycardia caused by refractory focal atrial tachycardia (n=1). Ivabradine was evaluated on Heart rate normalization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: